RxDoctor Payments Data

Ashra Mirza, NP

Family · Livonia, MINPI 1316329246

Payments from drug & device makers

$5,907in general payments, 2019–2025

Across 229 payments — averaging $25.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • AbbVie$1K
  • Boston Scientific$522
  • Collegium Pharmaceutical, Inc.$410
  • Pfizer$351
  • Nalu Medical, Inc.$350
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$71112%
  • Food & beverage$5,19688%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,907 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$68,082
Medicare patients
130
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide31$69,551
BelbucaBuprenorphine Hcl72$54,791
Nurtec OdtRimegepant Sulfate18$24,872
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen844$11,638
Buprenorphine43$8,717
Lidocaine65$7,527
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl33$7,349
Gabapentin568$5,535
OxycontinOxycodone Hcl16$5,119
Tizanidine Hcl328$5,112
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen211$3,494
Diclofenac Sodium83$3,190
Pregabalin233$2,586
Methocarbamol83$1,487
Baclofen72$1,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$324$69,55131 claims
Collegium Pharmaceutical, Inc.Belbuca$410$54,79172 claims
PfizerNurtec Odt$351$24,87218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →